Viridian Therapeutics Inc (VRDN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Viridian Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 19.30 $ — 29% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
5/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 40.4%
- Exp. sales growth 3Y > 5% 80.8%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 80.8%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -47.4%
- ROCE > 15% -43.9%
- Expected return > 10% 57.8%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 241.9% passed
- More than 10% revenue growth is expected for the coming year 627.1% passed
- Share count grows by less than 3% a year 38.3% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 22,969.1% passed
- Gross margin at 40% or higher and without meaningful erosion 100.0% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 824 m net cash passed
- Operating cash flow covers the profits of the last three years 157 m failed
- Return on capital at 15% or higher, or up versus two years ago -43.9% failed
- Insiders hold at least 10% or are net buyers 0.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 87.2% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 16
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.80 | -4.72 – -3.26 | 28 | -14.4% | 12 |
| 12/31/2027 | -2.63 | -4.19 – -1.65 | 232 | 30.7% | 12 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.97 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.00 | – | 0 | 0.00 | -110,729.20 | -73 | -73 |
| 2025: Q1 | -1.07 | – | 0 | 0.00 | -120,711.10 | -93 | -93 |
| 2025: Q2 | -1.23 | – | 0 | 4.20 | -134,313.30 | -75 | -75 |
| 2025: Q3 | -0.42 | – | 71 | 81,958.10 | -49.00 | -85 | -85 |
| 2025: Q4 | -1.42 | – | 0 | 83.30 | -91,178.00 | -24 | -24 |
| 2026: Q1 | -1.03 | – | 0 | 95.80 | -74,397.90 | -120 | -120 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 3 | -13 | -13 | -17.57 | -7 | 0 | 4 |
| 2017 | 4 | -27 | -27 | -20.66 | -28 | 39 | 52 |
| 2018 | 8 | -33 | -33 | -16.57 | -27 | 51 | 66 |
| 2019 | 4 | -42 | -42 | -20.04 | -36 | 16 | 30 |
| 2020 | 1 | -110 | -111 | -31.13 | -30 | 120 | 131 |
| 2021 | 3 | -80 | -79 | -6.66 | -55 | 188 | 204 |
| 2022 | 2 | -134 | -130 | -4.05 | -94 | 395 | 435 |
| 2023 | 0 | -254 | -238 | -5.31 | -184 | 442 | 490 |
| 2024 | 0 | -299 | -270 | -3.98 | -232 | 672 | 742 |
| 2025 | 71 | -363 | -343 | -4.04 | -276 | 722 | 899 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Viridian Therapeutics, Inc. beschäftigt sich mit der Entdeckung, Entwicklung und Vermarktung von Behandlungen für schwere und seltene Krankheiten.
| Employees | 252 |
|---|---|
| Headquarters | Waltham, MA |
| Address | 221 Crescent Street, 02453 Waltham, United States |
| Phone | 617 272 4600 |
| Website | viridiantherapeutics.com |
| IPO Date | 18. Jun 2014 |
| ISIN | US92790C1045 |
| Stock Split | 1:15 on 11/13/2020 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Stephen F. Mahoney J.D., MBA | CEO, President & Director | 1971 |
| Seth Harmon | Chief Financial Officer | 1981 |
| Thomas W. Beetham J.D., MBA | Chief Operating Officer | 1970 |
| Jennifer Tousignant J.D. | Chief Legal Officer & Corporate Secretary | 1973 |
| Radhika Tripuraneni M.D., M.P.H. | Chief Medical Officer | 1980 |
| Eric N. Olson Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | – |
| Michael R. Bristow M.D., Ph.D. | Co-Founder & Member of the Scientific Advisory Board | 1945 |
| Marvin H. Caruthers Ph.D. | Co-Founder & Scientific Advisory Board Member | 1940 |
| Vahe Bedian Ph.D. | Co-Founder & Scientific Advisor | – |
| Melissa Manno | Chief Human Resources Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.